Vol 80, No 2 (2022)
Expert opinion
Published online: 2022-01-25
An expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure: Heart failure guidelines from a national perspective
Abstract
The Polish expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of heart failure points to differences in many aspects related to heart failure in Poland compared with other European countries. These differences include population issues, epidemiology, diagnostic and treatment options, or the organization of healthcare. This expert opinion also includes a review of new results of clinical trials completed after the publication of the ESC guidelines.
Keywords: heart failurediagnosis and therapymultidisciplinary approachguidelines
References
- Adamo M, Gardner RS, McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Heart failure in Poland Reality, costs, suggestions for improving the situation [article in Polish]. Kałużna-Oleksy M. (ed). 2020. Available online: https://marfan.org.pl/wp-content/uploads/2021/01/Niewydolnos%CC%81c%CC%81-RAPORT-A4-2021-NET.pdf. (Access: January 25, 2022).
- Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021; 23(6): 872–881.
- McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation. 2021; 143(9): 875–877.
- DeVore AD, Braunwald E, Morrow DA, et al. Angiotensin-Neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
- Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019; 21(8): 998–1007.
- Morrow D, Velazquez E, DeVore A, et al. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. 2019; 139(19): 2285–2288.
- Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42(35): 3427–3520.
- Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–1461.
- Lelonek M, Stopczyńska I, Korościk E, et al. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure. Adv Clin Exp Med. 2020; 29(11): 1305–1312.
- Grayburn PA, Sannino A, Packer M. Distinguishing proportionate and disproportionate subtypes in functional mitral regurgitation and left ventricular systolic dysfunction. JACC Cardiovasc Imaging. 2021; 14(4): 726–729.
- Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013; 34(36): 2795–2803.
- Verdecchia P, Cavallini C, Coiro S, et al. Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease. Eur Heart J Suppl. 2021; 23(Suppl E): E172–E176.
- Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020; 396(10266): 1895–1904.
- Elliott PM, Anastasakis A, Asimaki A, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail. 2019; 21(8): 955–964.
- Dziewięcka E, Rubiś P. Mortality risk assessment in dilated cardiomyopathy: the Krakow DCM Risk Score. Kardiol Pol. 2021; 79(2): 215–216.
- Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019; 393(10166): 61–73.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021; 23(4): 512–526.
- Maurer M, Schwartz J, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379(11): 1007–1016.
